File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lowering the doses of mifepristone and gemeprost for early abortion: A randomised controlled trial

TitleLowering the doses of mifepristone and gemeprost for early abortion: A randomised controlled trial
Authors
Issue Date2001
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJOG
Citation
British Journal Of Obstetrics And Gynaecology, 2001, v. 108 n. 7, p. 738-742 How to Cite?
AbstractObjective: To test the efficacy of lower doses of mifepristone and gemeprost for medical induction of early abortion. Design: Randomised controlled trial. Participants were blinded as to the therapy and physicians to the dose of mifepristone. Setting: Thirteen hospital gynaecological units in different continents. Participants: 1224 healthy pregnant women requesting medical abortion at <57 days from last menses. Intervention: Random allocation to one of four regimens: mifepristone 50 mg by mouth followed by either 0.5 mg or 1.0 mg gemeprost vaginally on day 3; mifepristone 200 mg by mouth followed by either 0.5 mg or 1.0 mg gemeprost vaginally. We concealed the allocation sequence from clinicians enrolling participants, and maintained double blinding throughout. Main outcome measures: Incidence of complete abortion; subordinate outcome measures included side effects such as vomiting and fall in haemoglobin, as well as the need for emergency curettage and blood transfusion. Results: The success rate was significantly related to the dose of mifepristone. The relative risk of failure to have a complete abortion with the lower dose of mifepristone was 1.6 (95% CI: 1.1-2.3) times that with the higher dose. The relative risk of failure with the lower dose of gemeprost (1.3; 95% CI: 0.9-1.8) did not reach statistical significance. Conclusions: A single dose of mifepristone 50 mg followed by gemeprost is inadequate for early medical abortion. There was no significant difference in side effects between the four treatment groups.
Persistent Identifierhttp://hdl.handle.net/10722/173250
ISSN
2001 Impact Factor: 2.321
References

 

DC FieldValueLanguage
dc.contributor.authorTempleton, Aen_US
dc.contributor.authorDhall, GIen_US
dc.contributor.authorCalder, Aen_US
dc.contributor.authorGomezAlzugaray, Men_US
dc.contributor.authorHo, PCen_US
dc.contributor.authorPretnarDarovec, Aen_US
dc.contributor.authorSikazwe, Cen_US
dc.contributor.authorJunKang, Cen_US
dc.contributor.authorPrasad, RNVen_US
dc.contributor.authorBygdeman, Men_US
dc.contributor.authorKóvacs, Len_US
dc.contributor.authorKavkasidze, Gen_US
dc.contributor.authorLiJuan, Sen_US
dc.contributor.authorNoonan, Een_US
dc.contributor.authorAli, Men_US
dc.contributor.authorPeregoudov, Aen_US
dc.contributor.authorLaperrière, Nen_US
dc.contributor.authorVon Hertzen, Hen_US
dc.contributor.authorGrimes, Den_US
dc.contributor.authorAli, Men_US
dc.date.accessioned2012-10-30T06:28:48Z-
dc.date.available2012-10-30T06:28:48Z-
dc.date.issued2001en_US
dc.identifier.citationBritish Journal Of Obstetrics And Gynaecology, 2001, v. 108 n. 7, p. 738-742en_US
dc.identifier.issn0306-5456en_US
dc.identifier.urihttp://hdl.handle.net/10722/173250-
dc.description.abstractObjective: To test the efficacy of lower doses of mifepristone and gemeprost for medical induction of early abortion. Design: Randomised controlled trial. Participants were blinded as to the therapy and physicians to the dose of mifepristone. Setting: Thirteen hospital gynaecological units in different continents. Participants: 1224 healthy pregnant women requesting medical abortion at <57 days from last menses. Intervention: Random allocation to one of four regimens: mifepristone 50 mg by mouth followed by either 0.5 mg or 1.0 mg gemeprost vaginally on day 3; mifepristone 200 mg by mouth followed by either 0.5 mg or 1.0 mg gemeprost vaginally. We concealed the allocation sequence from clinicians enrolling participants, and maintained double blinding throughout. Main outcome measures: Incidence of complete abortion; subordinate outcome measures included side effects such as vomiting and fall in haemoglobin, as well as the need for emergency curettage and blood transfusion. Results: The success rate was significantly related to the dose of mifepristone. The relative risk of failure to have a complete abortion with the lower dose of mifepristone was 1.6 (95% CI: 1.1-2.3) times that with the higher dose. The relative risk of failure with the lower dose of gemeprost (1.3; 95% CI: 0.9-1.8) did not reach statistical significance. Conclusions: A single dose of mifepristone 50 mg followed by gemeprost is inadequate for early medical abortion. There was no significant difference in side effects between the four treatment groups.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJOGen_US
dc.relation.ispartofBritish Journal of Obstetrics and Gynaecologyen_US
dc.subject.meshAbortifacient Agents, Nonsteroidal - Administration & Dosageen_US
dc.subject.meshAbortifacient Agents, Steroidal - Administration & Dosageen_US
dc.subject.meshAbortion, Induced - Methodsen_US
dc.subject.meshAdministration, Intravaginalen_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdulten_US
dc.subject.meshAlprostadil - Administration & Dosage - Analogs & Derivativesen_US
dc.subject.meshDouble-Blind Methoden_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMifepristone - Administration & Dosageen_US
dc.subject.meshPregnancyen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleLowering the doses of mifepristone and gemeprost for early abortion: A randomised controlled trialen_US
dc.typeArticleen_US
dc.identifier.emailHo, PC:pcho@hku.hken_US
dc.identifier.authorityHo, PC=rp00325en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0306-5456(00)00171-6en_US
dc.identifier.pmid11467701-
dc.identifier.scopuseid_2-s2.0-0034893262en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034893262&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume108en_US
dc.identifier.issue7en_US
dc.identifier.spage738en_US
dc.identifier.epage742en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridTempleton, A=7201988374en_US
dc.identifier.scopusauthoridDhall, GI=7004268485en_US
dc.identifier.scopusauthoridCalder, A=7102367254en_US
dc.identifier.scopusauthoridGomezAlzugaray, M=6506187382en_US
dc.identifier.scopusauthoridHo, PC=7402211440en_US
dc.identifier.scopusauthoridPretnarDarovec, A=6602910640en_US
dc.identifier.scopusauthoridSikazwe, C=15746638500en_US
dc.identifier.scopusauthoridJunKang, C=20234747000en_US
dc.identifier.scopusauthoridPrasad, RNV=24384036500en_US
dc.identifier.scopusauthoridBygdeman, M=7101634701en_US
dc.identifier.scopusauthoridKóvacs, L=24348044800en_US
dc.identifier.scopusauthoridKavkasidze, G=6507999137en_US
dc.identifier.scopusauthoridLiJuan, S=36830550600en_US
dc.identifier.scopusauthoridNoonan, E=36153506600en_US
dc.identifier.scopusauthoridAli, M=35515013100en_US
dc.identifier.scopusauthoridPeregoudov, A=6603256918en_US
dc.identifier.scopusauthoridLaperrière, N=7004015563en_US
dc.identifier.scopusauthoridVon Hertzen, H=7004390324en_US
dc.identifier.scopusauthoridGrimes, D=36045728400en_US
dc.identifier.scopusauthoridAli, M=7404486066en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats